Author

P. Abbink

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:non-human primate· 1 Assay:scRNA-seq· 1 Approach:statistical model· 1

Frequent Co-Authors

D. H. Barouch· 2 shared A. B. Ward· 1 shared A. Finzi· 1 shared A. Khandhar· 1 shared B. Doranz· 1 shared B. Granger· 1 shared B. Murrell· 1 shared B. Nogal· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

D. H. Barouch

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Integrated technology platform for accelerated discovery of antiviral antibody therapeutics

P. Gilchuk, R. G. Bombardi, J. H. Erasmus, Q. Tan, R. S. Nargi, C. Soto, P. Abbink, T. J. Suscovich, L. A. Dunellin, A. Khandhar, J. Archer, J. Liang, M. E. Fouch, E. Davidson, B. Doranz, , R. H. Carnahan

This study develops an integrated platform to rapidly discover and validate potent antiviral human monoclonal antibodies against Zika virus.

bioRxiv · May 12, 2020Immunology

Vaccine-induced protection from homologous Tier 2 simian-human immunodeficiency virus challenge in nonhuman primates

M. G. Pauthner, J. P. Nkolola, C. Havenar-Daughton, B. Murrell, S. M. Reiss, R. Bastidas, J. Prevost, R. Nedellec, B. von Bredow, P. Abbink, C. A. Cottrell, D. W. Kulp, T. Tokatlian, B. Nogal, M. Bianchi, , D. R. Burton

This study shows that high serum neutralizing antibody titers from Env protein vaccination protect rhesus macaques from Tier 2 SHIV challenge, with ~1:500 ID50 titers providing over 90% protection.

bioRxiv · Oct 29, 2018Immunology